Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

Adalimumab in the treatment of arthritis

Authors Philip J Mease

Published 15 March 2007 Volume 2007:3(1) Pages 133—148

Philip J Mease

Seattle Rheumatology Associates, Seattle, WA, USA

Abstract: Tumor necrosis factor (TNF) has been implicated in a number of arthritic disease states, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Adalimumab is the first fully human, high-affinity, recombinant immunoglobulin G1 (IgG1) anti-TNF monoclonal antibody. Adalimumab in combination with methotrexate or standard antirheumatic therapies, or as monotherapy, is effective in the treatment of adults with active rheumatoid arthritis who have had an inadequate response to disease-modifying antirheumatic drugs. Adalimumab is also effective in the treatment of patients with moderately to severely active psoriatic arthritis, improving both joint and skin manifestations of the disease as well as disability due to joint damage. In the Adalimumab Trial Evaluating Long-term Efficacy and Safety in Ankylosing Spondylitis (ATLAS), adalimumab significantly reduced the signs and symptoms of active ankylosing spondylitis and established a sustained clinical response in patients who had an inadequate response or intolerance to nonsteroidal antiinflammatory drug therapy. Overall, across these indications, adalimumab demonstrated a rapid onset of action, sustained efficacy with long-term treatment, and was well-tolerated, with few patients discontinuing treatment because of adverse events. The safety profile was similar to other TNF antagonists. Inhibition of TNF activity by adalimumab also significantly improved physical functioning and quality of life measures.

Keywords: Adalimumab, TNF antagonists, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis

Download Article [PDF] 

Readers of this article also read:

MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP

Pang Y, Mao H, Shen L, Zhao Z, Liu R, Liu P

OncoTargets and Therapy 2014, 7:587-597

Published Date: 23 April 2014

Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry

Gregersen H, Larsen CB, Haglund A, Mortensen R, Andersen NF, Nørgaard M

Clinical Epidemiology 2013, 5:321-326

Published Date: 27 August 2013

Treatment of non-alcoholic fatty liver disease

Keith G Tolman, Anthony S Dalpiaz

Therapeutics and Clinical Risk Management 2007, 3:1153-1163

Published Date: 15 January 2008

Pharmacological causes of hyperprolactinemia

Daria La Torre, Alberto Falorni

Therapeutics and Clinical Risk Management 2007, 3:929-951

Published Date: 15 November 2007

Drug management in chronic rhinosinusitis: identification of the needs

Jean-Baptiste HPJ Watelet, Philippe H Eloy, Paul B van Cauwenberge

Therapeutics and Clinical Risk Management 2007, 3:47-57

Published Date: 15 March 2007

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007

Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia

R Lozano, MG Peralta Concha, A Montealegre, L de Leon, J Ortiz Villalba, et al

Therapeutics and Clinical Risk Management 2007, 3:149-155

Published Date: 15 March 2007

Acne phototherapy with a 1450-nm diode laser: an open study

Natusko Konishi, Hideki Endo, Naoki Oiso, Shigeru Kawara, Akira Kawada

Therapeutics and Clinical Risk Management 2007, 3:205-209

Published Date: 15 March 2007